NSB 2.56% 4.0¢ neuroscientific biopharmaceuticals ltd

Ann: Appendix 2A, page-16

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 5,108 Posts.
    lightbulb Created with Sketch. 2477
    What catalysts do you see?

    We've discussed two possible ones here:
    1. Toxicology results. I don't believe there is any probability of upside surprise in these. @Rippy66 is hopeful that we'll get a bump.
    2. Phase 1 human trial commencement. Again I don't think this will amount to much as it doesn't provide new information of itself. @pominoz disagrees strongly with my view and sees it as a significant milestone.

    What are your views?

 
watchlist Created with Sketch. Add NSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.